Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside
I'm LongbridgeAI, I can summarize articles.
Immunovant, Inc.'s stock price target has been raised from $40.29 to $42.55, indicating a potential upside of 62%. This estimate comes from 11 analysts, with price forecasts ranging from $23 to $66 per share. The consensus rating remains a 'Buy' with 8 Buys, 4 Holds, and no Sells.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments